Top Research to Be Presented in 2021 ASCO Annual Meeting Press Program

ALEXANDRIA, Va. - Advances in the treatment of prostate, breast, lung, and renal cancers as well as screening, prevention, access to care, immunotherapy, and precision medicine will be highlighted in the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting's official Press Program. Studies featured in the Press Program are among the more than 4,900 abstracts part of the Meeting.

The 2021 ASCO Annual Meeting, taking place online June 4-8, will bring together one of the largest, most diverse audiences in oncology and provide engaging broadcast and on-demand presentations of the latest cutting-edge research. The theme of this year's meeting is Equity: Every Patient. Every Day. Everywhere. and discussions during the meeting will help identify ways to ensure that all patients have access to and benefit from the latest cancer advances and high-quality cancer care.

More than 2,450 abstracts will be presented and an additional 2,450 abstracts will be published online. Most abstracts will be publicly released on ASCO's Meeting Library on Wednesday, May 19, at 5:00 p.m. ET. Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released online on Thursday, June 3, at 5:00 p.m. ET.

EMBARGOED PRESSCAST - Friday, May 14, 10:45 a.m.-12:00 p.m. ET
An embargoed presscast (online press briefing) for credentialed media will be held on May 14 to highlight the following studies (embargo will lift on Wednesday, May 19, 2021, at 5:00 p.m. ET):

• Findings from a study evaluating the association of state Medicaid income eligibility limits and long-term survival after cancer diagnosis in the United States (Abstract 6512)
• Results from a study looking at the association of increased prostate-specific antigen (PSA) screening and prostate cancer outcomes in younger African American patients (Abstract 5004)
• A study examining the effects of screening and vaccination on HPV-related cancers in the United States over the last 15 years (Abstract 107)
• The findings from the phase III global IMpower010 study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected non-small cell lung cancer (Abstract 8500)
• Primary phase III results from RELATIVITY-047 evaluating combination treatment with two immunotherapies (relatlimab plus nivolumab) versus nivolumab in first-line treatment for patients with advanced melanoma (Abstract 9503)

EMBARGOED PRESSCAST - Friday, May 28, 11:30 a.m.-1:00 p.m. ET
An embargoed presscast for media will be held on May 28 to highlight the following studies (embargo will lift on June 3 at 5:00 p.m. ET):

• The findings from the randomized, placebo-controlled phase III OlympiA trial investigating the use of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1 and BRCA2 mutations and high risk HER2-negative primary breast cancer (Abstract LBA1, Plenary)
• Results from the phase III VISION trial studying lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (Abstract LBA4, Plenary)
• The results of JUPITER-02, a randomized study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (LBA2, Plenary)
• Results from the randomized, double-blind, phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo after surgery in patients with renal cell carcinoma (Abstract LBA5, Plenary)
• First results from the CheckMate 648 study evaluating nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (Abstract LBA4001)
• Findings from the phase III OUTBACK trial exploring the use of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (Abstract LBA3, Plenary)

MEDIA RESOURCES

Apply for/renew ASCO media credentials: To participate in the embargoed presscasts, access embargoed press materials, and/or view presentations from the 2021 ASCO Annual Meeting, please visit ASCO's Media Headquarters at mediahq.asco.org.

• Step-by-step instructions for renewing your ASCO media credentials
  Please note: ASCO will send you an email when it's time to renew your credentials; if you would like to renew now, please email [email protected] so that ASCO staff can set your account to renew
• Step-by-step instructions for requesting ASCO media credentials for the first time

Annual Meeting Media Resource Center: Visit asco.org/AMMRC for press releases, the presscast schedule, embargo policies, meeting information, and to access the Virtual Press Room (an online repository of corporate and institutional press materials from third-party organizations).

Cancer.Net: ASCO's website for oncologist-approved cancer information

Founded in 1964, the American Society of Clinical Oncology, Inc. (the Society) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO® represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality and equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports the Society by funding groundbreaking research and education across cancer's full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.